L3VLUP
ProSign in

ABBV · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ABBVVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ABBV
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterABBVVRTX
Q3 202031 holders, $16.4bn31 holders, $21.9bn
Q4 202027 holders, $18.4bn30 holders, $18.4bn
Q1 202126 holders, $16.6bn31 holders, $15.4bn
Q2 202129 holders, $16.0bn30 holders, $12.7bn
Q3 202126 holders, $12.8bn35 holders, $10.1bn
Q4 202129 holders, $15.3bn28 holders, $12.4bn
Q1 202225 holders, $18.8bn23 holders, $16.1bn
Q2 202222 holders, $17.4bn25 holders, $18.1bn
Q3 202227 holders, $15.4bn22 holders, $18.4bn
Q4 202225 holders, $17.8bn28 holders, $18.4bn
Q1 202329 holders, $17.0bn26 holders, $21.4bn
Q2 202332 holders, $13.2bn27 holders, $24.7bn
Q3 202337 holders, $15.9bn33 holders, $24.3bn
Q4 202335 holders, $15.5bn32 holders, $28.6bn
Q1 202425 holders, $18.9bn31 holders, $29.8bn
Q2 202428 holders, $19.3bn29 holders, $33.4bn
Q3 202426 holders, $23.1bn27 holders, $33.5bn
Q4 202425 holders, $20.5bn26 holders, $28.5bn
Q1 202531 holders, $24.5bn21 holders, $35.4bn
Q2 202539 holders, $20.2bn21 holders, $32.3bn
Q3 202534 holders, $27.1bn22 holders, $25.9bn
Q4 202523 holders, $27.7bn26 holders, $31.8bn
Q1 202627 holders, $26.8bn25 holders, $31.8bn
Q2 202630 holders, $33.2bn26 holders, $34.6bn
ABBV

Abbvie Inc

Holders
25
Reported value
$20.5bn
Buyers
11
Sellers
12

Breadth -1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$28.5bn
Buyers
14
Sellers
13

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 36 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ABBV (10)

Acadian Asset Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Caxton Associates LLP, Dodge & Cox, Eisler Capital Management Ltd, Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP

Only VRTX (11)

ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Millennium Management LLC, PDT Partners LLC, Voloridge Investment Management LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →